PMID- 24944389
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140619
LR  - 20211021
IS  - 0011-393X (Print)
IS  - 0011-393X (Linking)
VI  - 64
IP  - 7
DP  - 2003 Jul
TI  - Comparison of candesartan and felodipine alone and combined in the treatment of 
      hypertension: a single-center, double-blind, randomized, crossover trial.
PG  - 380-8
LID - 10.1016/S0011-393X(03)00128-0 [doi]
AB  - BACKGROUND: In the past decade, many studies have indicated that the combination 
      of low doses of different classes of antihypertensive agents may be more 
      efficacious than monotherapy while minimizing the likelihood of dose-dependent 
      adverse effects (AEs). OBJECTIVE: The aim of this study was to determine whether 
      combination therapy with lower doses of candesartan and a calcium antagonist, 
      felodipine, would be more effective and tolerable in controlling mild to moderate 
      hypertension compared with either drug used alone. METHODS: In this 18-week, 
      single-center, double-blind, crossover study, patients with mild to moderate 
      essential hypertension were randomized to 1 of 2 treatment groups after a 2-week 
      placebo washout period. Patients in group 1 received candesartan 16 mg once daily 
      and patients in group 2 received felodipine 5 mg once daily, for 6 weeks. All 
      patients then received half-dose combination therapy (candesartan 8 mg plus 
      felodipine 2.5 mg, once daily) for 6 weeks. Finally, patients received 6 weeks of 
      monotherapy with the alternate medication (group 1 received felodipine 5 mg once 
      daily and group 2 received candesartan 16 mg once daily). RESULTS: Thirty 
      patients (18 men, 12 women; mean [SD] age, 54.0 [4.9] years; range, 39-62 years) 
      were included in the study. During both monotherapy periods, candesartan and 
      felodipine significantly reduced blood pressure (BP) (both P<0.001). BP further 
      decreased with combination therapy (P<0.001 in both groups). Overall, 90.0% 
      (27/30) of the patients achieved the target BP at the end of combination therapy. 
      The incidence of AEs was similar with combination therapy compared with either 
      monotherapy. CONCLUSIONS: In this study population, candesartan and felodipine 
      had additive effects when used in combination, even at low doses, in the 
      treatment of hypertension. Therefore, the combination of candesartan and 
      felodipine is an effective alternative to that of candesartan and 
      hydrochlorothiazide.
FAU - Nalbantgil, Sanem
AU  - Nalbantgil S
AD  - Department of Cardiology, Ege University Medical School, Izmir, Turkey.
FAU - Zoghi, Mehdi
AU  - Zoghi M
AD  - Department of Cardiology, Ege University Medical School, Izmir, Turkey.
FAU - Ozerkan, Filiz
AU  - Ozerkan F
AD  - Department of Cardiology, Ege University Medical School, Izmir, Turkey.
FAU - Boydak, Bahar
AU  - Boydak B
AD  - Department of Cardiology, Ege University Medical School, Izmir, Turkey.
FAU - Nalbantgil, Istemi
AU  - Nalbantgil I
AD  - Department of Cardiology, Ege University Medical School, Izmir, Turkey.
FAU - Onder, Remzi
AU  - Onder R
AD  - Department of Cardiology, Ege University Medical School, Izmir, Turkey.
FAU - Akin, Mustafa
AU  - Akin M
AD  - Department of Cardiology, Ege University Medical School, Izmir, Turkey.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Ther Res Clin Exp
JT  - Current therapeutic research, clinical and experimental
JID - 0372621
PMC - PMC4053044
OTO - NOTNLM
OT  - candesartan
OT  - combination therapy
OT  - felodipine
OT  - hypertension
EDAT- 2003/07/01 00:00
MHDA- 2003/07/01 00:01
PMCR- 2003/07/01
CRDT- 2014/06/20 06:00
PHST- 2003/06/06 00:00 [accepted]
PHST- 2014/06/20 06:00 [entrez]
PHST- 2003/07/01 00:00 [pubmed]
PHST- 2003/07/01 00:01 [medline]
PHST- 2003/07/01 00:00 [pmc-release]
AID - S0011-393X(03)00128-0 [pii]
AID - 10.1016/S0011-393X(03)00128-0 [doi]
PST - ppublish
SO  - Curr Ther Res Clin Exp. 2003 Jul;64(7):380-8. doi: 10.1016/S0011-393X(03)00128-0.